Organ transplant recipients face a critical trade-off: suppress their immune system enough to prevent rejection while avoiding the dangerous infections and cancers that follow systemic immunosuppression. This dilemma has driven decades of research into localized approaches that could protect transplanted organs without compromising the recipient's broader immune defenses.
Researchers have engineered a sprayable coating called "Immune-shield" that delivers immunosuppressive drugs directly to transplanted tissue surfaces. The system uses bioengineered mussel adhesive proteins to create microgel particles that can be sprayed onto wet organ surfaces during surgery. These proteins naturally resist immune recognition due to their disordered molecular structure, while strongly adhering to biological tissues. The coating provides controlled, sustained release of cyclosporin A directly at the transplant site, maintaining therapeutic drug concentrations locally for extended periods.
In rat skin transplant experiments, the coating significantly reduced inflammatory cell infiltration and tissue rejection compared to untreated controls, achieving localized immunosuppression without detectable systemic drug levels. This represents a meaningful advance toward solving transplant medicine's central challenge. Current immunosuppressive regimens require lifelong systemic therapy with substantial risks including increased infection susceptibility, cardiovascular disease, and malignancy. A localized delivery system could potentially reduce these complications while maintaining graft survival. However, skin grafts represent a relatively simple transplant model. The approach will require validation in more complex organ systems and longer-term studies to assess durability and safety before clinical translation becomes feasible.